

DATAWorks! Distance of the second sec

How To: Request Studies on Vivli for the DataWorks! Prize

Vivli Platform Release 3.4

August 5, 2024

Contents

1.	1.0 Requesting eligible Studies and completing a data request –Overview	3
	1.1 Add studies to your data request	4
	1.2 Completing a data request	5
	1.3 Adding Research Team Members	5
	1.4 Submitting your data request	
	2.0 Vivli Accelerated Review of your data request	11
	3.0 Data Use Agreement	
	4.0 Downloading data	
	5.0 Help and Support	14
	5.1Open Chat	14
	5.2 Support email	



1.0 Requesting eligible Studies and completing a data request – Overview

- Please refer to the DataWorks! Prize portal for information about the prize submission process. As Vivli is a managed access platform, please do request any Vivli data in plenty of time to meet the deadlines for the prize so that you will have all the data you so that you have the full six months to complete your project.
- Please go to the DataWorks! Prize portal to find out more information and view the eligible studies. https://search.vivli.org/portal/dataworksprize. Please note: Only studies that appear as part of the Dataworks portal are eligible so please ensure when searching that a search criteria is the term Dataworksprize. If you have any questions about if a study is eligible, please reach out to Vivli via support@vivli.org.
- Once you have decided on studies that you want to include in your DataWorks! Prize submission, you will need to complete a Vivli data request form.
- You must be logged in as a Vivli user to begin your data request.
- If you do not have a Vivli account, you will need to set one up before beginning a data request. To learn more about creating a Vivli account, please review our <u>Vivli User Account Quick Start guide</u>.

If you are not logged in, you will be prompted to do so. After you log in, you will return to the search results window:

CENTER FOR GLOBAL CLINICAL RESEARCH DATA	1	ENQUIRY QUICK STUL	Y LOOKUP ✔ S	Sign up Log Ir
dataworksprize				CLOSE
STUDY DESIGN INTERVENTIONAL STUDIES		Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora	Log in to Re	equest Study
Select Multiple	~	IDE NCT04366089 110/2020	View Stu	dy Details
OBSERVATIONAL STUDIES		Intervention/treatment: Oxygen-ozone therapy, probiotic supplementation and Standard of care, SivoMixx (200 billion), Azithromycin, hydroxychloroquine	Number	enrolled:-
Select Multiple	~		Pha	se 2
STUDY PHASE		An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients	Login to Rd	aquaet Study
Select Multiple	~	IDs: NCT04322123 Brazil COVID Coalition Trial Condition or Disease: Coronavirus Infections Indervention/enstrement: Hordowshiptionaujae Oral Product. Hydroxychiproaujae + azithromycin	View Stu	dy Details
SPONSOR INFORMATION SPONSOR TYPE			Number er Pha	nrolled:667 use 3
Select Multiple	~			
SPONSOR		Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults	Log in to Re	quest Study
Select Multiple	~	IDs. KCT04369742 [20-0463 Condition or Disease: COVID-19 Intervention/treatment. Hydroxychioroquine (HCQ), Pacebo: Calcium citrate	View Stu	dy Details
SAMPLE SIZE	(Disabled)		Number er Pha	nrolled:128 use 2

1.1 Add studies to your data request

1. Starting a data request begins with the addition of studies. To add studies from a search to a Data Request Form, click on Request Study.



2. A dropdown will appear - click on +Add New Request:



3. A dialogue box will pop up where you can provide the Research Project Name for your research project. **Note:** Your Project name must match the "Title of Proposed Research" within the data request form. This can be edited before submitting the data request for review. After entering a research project name, click **Ok** to create the data request. **In the title, please start your Title with 2024 DataWorks! Prize**



4. To add an additional study to an existing data request, click on **Request Study.** Then click on the existing data request's title from the dropdown. Note: If you have multiple studies to add to your research project, add them to the same request by repeating this step for each study you want to request.



5. Once you have added all desired studies listed on the Vivli platform, you can complete the Data Request Form.

1.2 Completing a data request

To complete a data request, you must add all required information_to the Data Request Form. For guidance, please see<u>Vivli Data Request Form Worksheet</u>. Please note that the data request must include:

- The name, contact information, primary affiliation and position, country, qualifications, degrees and where the degrees were obtained of all team members.
- Conflict of Interest Statement
- The title of the proposed research with a description of the study design (which should match the Project name). Reminder: please begin your title with **2024 DataWorks! Prize**
- Lay summary explaining the relevance of the project to science and public health
- Studies
- Statistical Analysis Plan
- Information about funding
- Attestation (For all other fields, put the phrase n/a)

1.3 Adding Research Team Members

• Individuals activated for a data request will be able to view and edit the Data Request Form How-To: Requesting Studies on Vivli for DataWorks! Prize Version 3.4

- If your team member is from a different institution than the Lead Investigator and they would like to access the data, they will need to have a DUA in place from their institution before accessing the data.
- 1. If the Lead Investigator is also a Statistician Researcher, select the checkbox as shown below

Vivli			Home About	Members News & Events	Resources Find Studies
CENTER FOR GLOBAL CLINICAL RESEARCH DATA			ENQUIRY	QUICK STUDY LOOKUP 🗸 📑 MY DA	TA REQUESTS 🗕 RESEARCHER 🗸
Go Back Predicting Treatm	nent Response Edd Request Tite			Cancel	Save 🗸 Submit
Research Team	LEAD RESEARCHER	Activate user for accessing data reque	st	Lead Researcher is	also Statistician Researcher 🛛 👔
Research Proposal	First Name	Last Name		ORCID iD	
Studies	Ema		Position		
Statistical Analysis Plan	Employer, Company, Research Ins		Country - Select an Option -		~
Funding	Education, including the degree, discipline and institution where the specific to clinical data analysis.	e degree was granted, and professional o	qualifications that are relevant to the	e proposed research and are	Character Count: 0/1000
Other Information / File Attachments					
Attestations					
Chat					0
	Please list any real or potential conflicts of interest and describe ho	w these will be managed. If none, pleas	e enter None.		
	VM Access Admin Approval Based on Approved DUA				

2. To add additional team members, scroll down to add additional team members - click on **Add+** in the lower right corner, opposite **ADDITIONAL RESEARCHERS**:

Uivli	Home About Members News & Events Resources Find Studies
CENTER FOR GLOBAL CLINICAL RESEARCH DATA	ENQUIRY QUICK STUDY LOOKUP 🗸 📑 MY DATA REQUESTS 👔 RESEARCHER 🗸
«Go Back Predicting Trea	tment Respo EdiRequest Tile Cancel Save Submit
Research Team	Education, including the degree, discipline and institution where the degree was granted, and professional qualifications that are relevant to the proposed research and are specific to clinical data analysis.
Research Proposal Studies	
Statistical Analysis Plan	
Funding	Please list any real or potential conflicts of interest and describe how these will be managed. If none, please enter None.
Other Information / File Attachments	
Attestations	VM Access Admin Approval Based on Approved DUA DUA Approval Not Applicable
	ADDITIONAL RESEARCHERS

3. The following dialogue box will appear:

			Activate user	for accessing data request
First Name	Last Name		ORCID iD 📀	
Email (editable until user is invited to da		Position		
Employer, Company, Research Institute, or Primary A	Aff	Country - Select an Option -		~
Education, including the degree, discipline and institu specific to clinical data analysis.	ution where the degree was granted, and profe	ssional qualifications that are relevant	to the proposed research and are 📀	Character Count: 0/1000
Please list any real or potential conflicts of interest ar	nd describe how these will be managed. If non	e, please enter None.		
Please list any real or potential conflicts of interest a	nd describe how these will be managed. If non	e, please enter None.		
Please list any real or potential conflicts of interest a	nd describe how these will be managed. If non	e, please enter None.		
Please list any real or potential conflicts of interest an VM Access Admin Approval Based on Approved DUA	nd describe how these will be managed. If non	e, please enter None.		
Please list any real or potential conflicts of interest an VM Access Admin Approval Based on Approved DUA DUA Approval Not Applicable	nd describe how these will be managed. If non	e, please enter None.		

4. Note that the character limit in the Education text field is 1000 characters. If the number of characters entered

exceeds this limit, a pop up will appear alerting you that the Education/qualification field exceeds the limit:

First Name	Last Name		ORCID ID		
Ema		Position			
Employer, Company, Research Ins	Education or Qualifications I	Country Select as Option ength must be less			\sim
Education, including the degree, discipline and institution whe proposed research and are specific to clinical data analysis.	than or equal to 1000 charac ere the degree was granted, and	ters long protessional qualifications that	are relevant to the	Character Count: 1223/1000	
Please see below for my education including degree, disciplin Education of Lead Researcher: Bachelor's Degree from University of California, San Francisco Master's Degree from University of California, San Francisco v PhD from University of California, San Francisco where I obtai	ne and institution where the degr o where Iobtained a degree in B where Iobtained a degree in Epi ined a degree in Epidemiology in	ee wa granted. I also included (iological Life Sciences in 1998 demiology in 2000 2006	qualifications specific to	this analysis	
Other qualifications:					
					0
Please list any real or potential conflicts of interest and descr	ibe how these will be managed.	If none, please enter None.			

5. Note that if there is missing information in a required field in the Research Team section, the field will be outlined in red and a red exclamation mark will appear in the "Research Team tab" on the left side. Once the required field is input, the exclamation mark will disappear.

Go Back Increase in a	Ibuminuria in Diabetes patients	Edil Request Tille		Cance	el Save 🗸 Submit
esearch Team	LEAD RESEARCHER - No Account	Activate user for access	sing data request	Lead Research	her is also Statistician Researcher 🛛 🥝
esearch Proposal	First Name Sarah	Last Name Jones		ORCID ID	
tudies	Email (editable until user is invited to data sarah.jones@ucsd.edu		Position		
tatistical Analysis Plan	Employer, Company, Research Institute, or Primary A UCSD	ffil	Country United States of Americ	a	~
unding ther Information / File Attachments	Education, including the degree, discipline and institut specific to clinical data analysis. PhD Biostatistics UCSD 1999 MS Biostatistics UCSD 1995	tion where the degree was granted, and profession	onal qualifications that are relev	ant to the proposed research and are	Character Count: 54/1000
inding ther Information / File Attachments testations	Education, including the degree, discipline and institut specific to clinical data analysis. PhD Biostatistics UCSD 1999 MS Biostatistics UCSD 1995	tion where the degree was granted, and profession	onal qualifications that are relev	ant to the proposed research and are	Character Count: 54/1000
unding ther Information / File Attachments testations hat	Education, including the degree, discipline and institut specific to clinical data analysis. PhD Biostatistics UCSD 1999 MS Biostatistics UCSD 1995	tion where the degree was granted, and profession	onal qualifications that are relev	ant to the proposed research and are	Character Count: 54/1000
Inding her Information / File Attachments testations	Education, including the degree, discipline and institut specific to clinical data analysis. PhD Biostatistics UCSD 1999 MS Biostatistics UCSD 1995 Please list any real or potential conflicts of interest and None	tion where the degree was granted, and profession	onal qualifications that are relev	ant to the proposed research and are	Character Count: 54/1000

6. Complete all fields, and click



- 7. Please ask the research team member to "sign up" for a Vivli account. They can follow Section 1.0 of the <u>Vivli</u> <u>User Account Quick Start guide</u>
- 8. Once the Research team members have created their Vivli account, you can activate them for accessing the Data Request Form by checking the checkbox **Activate user for accessing data request** and then click **OK**:

ADDITIONAL RESEARCHER				Activate user f	for accessing da	ita request 🕜
First Name	Last Name		ORCID iD	0		
Email (editable until user is invited to da		Position				
Employer, Company, Research Institute, or Primary Aff		Country - Select an Option -				~
Education, including the degree, discipline and institution wh proposed research and are specific to clinical data analysis.	ere the degree was granted, ar	d professional qualifications that are	e relevant to th	ie 🧉	Character C 0/1000	ount:
						0
Please list any real or potential conflicts of interest and desc	ribe how these will be managed	d. If none, please enter None.				
VM Access Admin Approval Based on Approved DUA DUA Approval Not Applicable						

9. On the main data request form, click **Save**. The team member will be automatically added to the data request.

< Go Back Increase in alk	ouminuria in Diabetes patie	TTS Edit Request Title		Cancel	Save 🗸 Submit	
Research Team	LEAD RESEARCHER / STATISTICIAN	Activate user for accessir	ng data request 🛛 🗹	Lead Researcher is also St	atistician Researcher 🛛 🕜	
Research Proposal	First Name Sarah	Last Name Jones		ORCID iD		
Studies	Email (editable until user is invited to data sarah.jones@ucsd.utorg	Email (editable until user is invited to data sarah.jones@ucsd.utorg		Position Biostatiscian		
Statistical Analysis Plan	Employer, Company, Research Institute, or I University of California, San Diego	Primary Affil	Country United States of An	nerica	~	
Other Information / File Attachments	Education, including the degree, discipline a relevant to the proposed research and are s PhD in Biostatistics (University of California, MS in Biostatistics (University of California,	nd institution where the degree wa pecific to clinical data analysis. San Diego, 1999) San Diego, 1995)	as granted, and profession	nal qualifications that are 🛛 🕜	Character Count: 129/1000	
Attestations						
Chat						
	Please list any real or potential conflicts of ir None	nterest and describe how these wil	l be managed. If none, ple	ease enter None.	0	

1.4 Submitting your data request

- Once the Data Request Form is complete, you may submit it for review.
- Please make sure that you have added all the eligible DataWorks Prize studies to your data request as adding it later will lead to additional delays.
- Before submitting a Data Request Form, the Lead Researcher must attest that all the information provided is accurate and complete:

Vivli	Home About Members News & Events Resources Find Studies
CENTER FOR GLOBAL CUNICAL RESEARCH DATE	ENDURY OLIOK STUDY LOOKUP 🗸 📑 MY DATA REQUESTS 👔 RESEARCHER 🗸
- Co Back Predicting Trea	tment Response to combination drugs in patients with type 2 diabetes (EdiRecond Tate)
Research Team	Certify Complete and Accurate
Research Proposal	Please check the box below to indicate that you as the Lead Researcher certify that the information provided is complete and accurate, and that you assume full responsibility for the research. I certify the information provided is complete and accurate.
Studies	Data Use Agreement Please note that all bata Requestors wishing to receive access to data must execute the Data Use Agreement (DUA) before the data can be provided. The DUA is the product of extensive negotiation with the consolizations that contribute (data to Veill, and as such, the agreement is non, appointed by the product of extensive negotiation with the
Statistical Analysis Plan	You can either fill out the DUA form and sign if digitally, or print it out, sign it and can be explored and a spread and suppression of a transaction, please upload it using the Signed Agreements tab of this data request (visible once the data request is submitted).
Funding	in you nave any questions regarding the DOA, prease contact a vivil admini at <u>subporte vivil or y</u> .
Other Information / File Attachments	
Attestations	
Chat	

• To submit a Data Request Form, simply click the blue box marked **Submit** in the top right corner of the screen:

Vivli	Home About Members News & Events Resources Find Studies
CENTER FOR GLOBAL CUNICAL RESEARCH DATE	ENDURY QUICK STUDY LOOKUP 🗸 😅 MY DATA REQUESTS 👔 RESEARCHER 🗸
Co Back Predicting Trea	tment Response to combination drugs in patients with type 2 diabetes Carcel Save Save
Research Team	Certify Complete and Accurate
Research Proposal	Please check the box below to indicate that you as the Lead Researcher certify that the information provided is complete and accurate, and that you assume full responsibility for the research.
Studies	Data Use Agreement Please note that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA) before the data can be provided. The DUA is the product of extensive negotiation with the organizations that contribute data to Vvii, and as such, the agreement is non-negotiable. The DUA form must be completed and signed and is available here.
Statistical Analysis Plan	You can either fill out the DUA form and sign it digitally, or print it out, sign it and scan it as PDF. Once the DUA has been signed by your organization, please upload it using the Signed Agreements tab of this data request (visible once the data request is submitted).
Funding	If you have any questions regarding the DUA, please contact a Vivili admin at support@vivili.org.
Other Information / File Attachments	
Attestations	
Chat	

• If the Submit button is still light blue and does not respond to a click, you have a required field that is not completed. You can look in each of the tabs on the left for a field outlined in red which indicates that a required field needs to be completed. Be sure to review the Research Proposal tab, Statistical Analysis Plan tab, Attestations (you need to check a checkbox) and the Research Team tab (you need to specify both a Lead Researcher and a Statistician. Please fill out all the details of the additional researcher(s), if applicable including the "Country" field). If there is missing information in the Research Team field, a red exclamation mark (!) will appear in the Research Team tab on the left.

Uivli	Home About Members News & Events Resources Find Studies
CENTER FOR GLOBAL CUNICAL RESEARCH DATE	ENQURY QUICK STUDY LOOKUP 🗸 😅 MY DATA REDUESTS 💽 RESEARCHER 🗸
COBX Predicting Trea	atment Response to combination drugs in patients with type 2 diabetes (California Cancel Save Subme
Research Team	Certify Complete and Accurate
Research Proposal	Please check the box below to indicate that you as the Lead Researcher certify that the information provided is complete and accurate, and that you assume full responsibility for the research.
Studies	Data Use Agreement Please note that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA) before the data can be provided. The DUA is the product of extensive negotiation with the organizations that creditions that and the data is such the acreement is non-secondaritie. This DUA form must be completed and simpled and is available hore.
Statistical Analysis Plan	You can either fill ou the DUA form and sign if digitally, or print it out, sign it and scan it as PDF. Once the DUA has been signed by your organization, please upload it using the Signed Agreements tab of this data request is submitted).
Funding	If you have any questions regarding the DUA, please contact a Vivil admin at support@vivil.org.
Other Information / File Attachments	
Attestations	
Chat	

2.0 Vivli Accelerated Review of your data request

Once submitted, your data request will go through a Vivli form check. It will be processed within 2 business days. We may request revisions. Please re-submit promptly.

3.0 Data Use Agreement

Once the request passes the form check, Vivli will send you the Data Use Agreement. All Data Requestors must execute the Data Use Agreement before receiving the data. The Data Use Agreement is the product of extensive negotiation with the organizations that contribute data to Vivli, and as such, the agreement is non-negotiable. If you have any questions about the Data Use Agreement, contact support@vivli.org.

- 1. Review the Data Use Agreement.
- 2. After your request is submitted and once Vivli checks the data request form is complete, Vivli will send you the Data Use Agreement via DocuSign for your signature and, if needed, that of an institutional official at your organization.
- 3. Once your data request is approved, Vivli will execute this document and load it into the platform under the signed agreements tab.

4.0 Downloading data

Once the Data Use Agreement is executed, you will receive a notification to download the data directly from the Vivli Platform using the following process:

 We way way being branched by the state of the state

Log in and open your approved data request:

1. Click on the study to get to the **Study details** screen:

							QUIC	K STUDY LOOKUP 🗸 (兽	MY DATA REQUESTS	
Phase II Onen Label, Dose-Escal	ation Study to	Determine th	e Safety, Tolerabi	lity and Efficacy	of Microsomal Triglyceride T	ransfer Protein	(MTP) Inhih	itor BMS-201038	n Patients Wi	ith
mozygous Familial Hypercholet	erolemia	Determine a	e ourery, referabl		or microsoniar mgryceniae n		()		in r utients m	
tudy Details Administrative Details	Download Dat	a Package								
hase					Condition or Disease					
hase 2 levention/treatment mitaplide					Homozygous Familial Hypercholes	terolemia				
hase 2 tervention/treatment omitapide rief Summary	usto the estate and	tolorshility of 4 do	cas of lomitavide (AEG	R.733: BMS-201028) ai	Homozygous Familial Hypercholes	lated through an ad	ditional 2 does 1	nucle quer a 16 work a	nied The second	1-m
hase 2 tervention/treatment omitapide ref Summay he primary objective of this study is to evaluat	uate the safety and ion of the pharmace	tolerability of 4 do	ses of lomitapide (AEG apide based on: - Per	R-733; BMS-201038) gi cent change in low-der	Homozygous Familial Hypercholes	alated through an ad	ditional 3 dose I triglycerides, ar	evels over a 16-week p d very low density lipo	eriod. The second protein cholesterc	iary ol (VLDL-C)
hase 2 tervention/treatment omitapide rief Summary he primary objective of this study is to eval pictures of this study included the evaluat oncentrations at the end of each 4-week do soprotein a [Lefa].	uate the safety and ion of the pharmac sing period compa	tolerability of 4 do odynamics of lomin ed to the Baselin	ses of lomitapide (AEG apide based on: - Per value of each paramet	R-733; BMS-201038) gi cent change in low-der ler at the end of the pr	Homozygous Familial Hypercholes ven as an initial low dose and then esci- sity (ipoprotein cholesterol (LDL-C), to vivous dose phase(s) Changes in of	alated through an ad tal cholesterol (TC), ther plasma lipoprote	ditional 3 dose l triglycerides, ar ins: apolipopro	evels over a 16-week p Id very low density lipo leins (apo B, apo Al, ap	eriod. The second orotein cholesterc All, apo Cill, apo	dary ol (VLDL-C) E) and
hase 2 tervention/treatment omitapide rief Summary he primary objective of this study is to eval bjectives of this study included the evaluat oncentrations at the end of each 4-week do poprotein a [Lp(a]).	uate the safety and ion of the pharmac sing period compa	tolerability of 4 do dynamics of Iomit ed to the Baselin	ses of lomitapide (AEG apide based on: - Per value of each paramet	R-733: BMS-201038) gi cent change in low-der ler at the end of the pr	Homozygous Familial Hypercholes ven as an initial low dose and then esc: sity [ipoprotein cholestero] (LDL-C), to avious dose phase(s), - Changes in of	alated through an ad tal cholesterol (TC), ther plasma lipoprote	ditional 3 dose I triglycerides, ar vins: apolipopro	avels over a 16-week p Id very low density lipo Reins (apo B, apo Al, ap	eriod. The second orotein cholesterc All, apo Cill, apo	dary ol (VLDL-C) E) and
hase 2 tervention/treatment omitapide nef Summary he primary objective of this study is to eval bjectives of this study included the evaluat oncentrations at the end of each 4-week do poprotein a [Lp(a]].	uate the safety and ion of the pharmac sing period compar	tolerability of 4 dd dynamics of Iomit red to the Baselin Sexes Eligible Fo	ses of lomitapide (AEG apide based on: - Per value of each paramet	R-733: BMS-201038) gi cent change in low-der er at the end of the pr	Homozygous Familial Hypercholes ven as an initial low dose and then esc: sity [lipoprotein cholestero] (LDL-C), to evious dose phase(s) Changes in of Accepts Healthy Volunteers	terolemia alated through an ad tal cholesterol (TC), ther plasma lipoproto	ditional 3 dose l triglycerides, ar ins: apolipopro Actual	avels over a 16-week p d very low density lipo leins (apo B, apo Al, ap Enrollment	eriod. The second orotein cholesterc All, apo Cill, apo	dary ol (VLDL-C) E) and
hase 2 tervention/treatment omitapide rief Summary Tap primary objective of this study is to evaluat procentrations at the end of each 4-week do poprotein a [Lp(a]]. ges Eligible For Study 3 Years and older	uate the safety and ion of the pharmac- sing period compa	tolerability of 4 dd odynamics of iomin ed to the Baselin Sexes Eligible Fo All	ses of lomitapide (AEG apide based on: - Per value of each paramet r Sludy	R-73: BMS-201038) gi cent change in low-der ler at the end of the pn	Homozygous Familial Hypercholes ven as an initial low dose and then esc: sity [lopprotein cholesterol (LDL-C), to evious dose phase(s) Changes in of Accepts Healthy Volunteers No	terolemia alated through an ad tal cholesterol (TC), ther plasma lipoprote	ditional 3 dose l trigiyeerides, ar ins: apolipopro Actual 6	avels over a 15-week p d very low density lipo leins (apo B, apo A), ap Enrollment	eriod. The second srotein cholesterc All, apo Cill, apo	dary ol (VLDL-C) E) and
hase 2 tervention/treatment omitapide rief Summary The primary objective of this study is to eval bjectives of this study included the evaluat oncentrations at the end of each 4-week do poprotein a [Lp[a]]. ges Eligible For Study Years and older tudy Start Date	uate the safety and ion of the pharmac sing period compa	tolerability of 4 dd odynamics of iomii ed to the Baselin Sexes Eligible Fo All	ses of Iomitapide (AEG apide based on: - Per value of each paramet r Study Study Completion	R-733: BMS-201038) gr cent change in low-der or at the end of the pr dete	Homozygous Familial Hypercholes ven as an initial low dose and then esc: sity [lpoprotein cholesterol (LDL-C), to evious dose phase(s), - Changes in or Accepts Healthy Volunteers No	terolemia alated through an ad tal cholesterol (TC), ther plasma lipoproto	ditional 3 dose I triglycerides, ar ins: apolipopro Actual 6	avels over a 15-veek j d very fow density lipo wins (apo B, apo Al, ap Enrollment	eriod. The second srotein cholesterc All, apo Cill, apo	dary ol (VLDL-C) E) and

Figure 27 - Study details screen

2. Click on Download Data Package:

Rhana II Onon Label Dava Facelo	tion Study to Determine the Sofety Televability	and Fffiance of Minnessen Triphoneside Transfer Deskin (MTD) Julikian DNC 204020 in Dataset With
mozygous Familial Hypercholete	rolemia	and Enreacy of Microsomal frigiveende fransier Protein (MTP) inhibitor BMS-201038 in Patients with
tudy Details Administrative Details	Download Data Package	
hase		Condition or Disease
		Homozygous Familial Hypercholesterolemia
rase 2 enerofoortroatment emitapide		
hase 2 terverion/treatment comitapide trief Summary		
hase 2 tervertion/treatment omitapide inf Summary he primary objective of this study is to evaluation spectres of this study included the evaluation spectres of the end of each 4-week dos soprotein a [Lp(a)].	ste the safety and tolerability of 4 doses of lomitapide (AEGR-731 n of the pharmacodynamics of lomitapide based on: - Percent ng period compared to the Baseline value of each parameter at	. BMS-201038) given as an initial low dose and then escalated through an additional 3 dose levels over a 16-week period. The secondary hange in low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), trighycerides, and very low density lipoprotein cholesterol (VLDL-C) the end of the previous dose phase(s). • Changes in other plasma lipoproteins: apolipoproteins (apo B, apo AI, apo AI, apo CII, apo E) and
hase 2 tervertion/treatment omitapide nef Summary he primary objective of this study is to evaluatio sncentrations at the end of each 4-week dos toprotein a [Lp(a)].	ete the safety and tolerability of 4 doses of lomitapide (AEGR-733 n of the pharmacodynamics of lomitapide based on: - Percent ng period compared to the Baseline value of each parameter at	BMS-201038) given as an initial low dose and then escalated through an additional 3 dose levels over a 16-week period. The secondary hange in low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), trighycerides, and very low density lipoprotein cholesterol (VLDL-C) the end of the previous dose phase(s). • Changes in other plasma lipoproteins: apolipoproteins (ap0, B, apo Al, apo Al, apo CII, apo E) and docente liketith: Universe
hase 2 tervertion/treatment omitapide nef Summary he primary objective of this study is to evalua- bectives of this study included the evaluation oncentrations at the end of each 4-week dosi poprotein a [Lp(a)]. ges Eliptile For Study 3 Years and older	ate the safety and tolerability of 4 doses of lomitapide (AEGR-73 n of the pharmacodynamics of lomitapide based on: - Percent ng period compared to the Baseline value of each parameter at Sexes Eligble For Study All	BMS-201038) given as an initial low dose and then escalated through an additional 3 dose levels over a 16-week period. The secondary hange in low-density lipoprotein cholesterol (VLDL-C hoad cholesterol (TC), triglycerides, and very low density lipoprotein cholesterol (VLDL-C head of the previous dose phase(s). • C hange in other plasma lipoproteins: apolipoproteins; apolipoproteins; apolipoprotein cholesterol (VLDL-C head of the previous dose phase(s). • C hange in other plasma lipoproteins; apolipoproteins; apolipoprotein; ap

Figure 28 - Download Data Package

3. This will take you to the Download screen:

Vivli		Home	About Members	News & Events Resources	Find Studies
CENTER FOR GLOBAL CLINICAL RESEARCH DATA			QUICK STUDY	LOOKUP 🗸 🔮 MY DATA REQUEST:	S 🕘 IDA SIM 🗸
A Phase II Open Label, Dose-Escalation Study to Homozygous Familial Hypercholeterolemia	Determine the Safety, Tolerability and Efficacy of	Microsomal Triglyceride Transfer Protein	(MTP) Inhibitor Bl	MS-201038 in Patients W	/ith
Study Details Administrative Details Download Data	i Package				
DOWNLOADABLE DATA PACKAGE - PRESS DOWNLOAD BUT	TON FOR EACH FILE				
Filename	Size	Uploaded By	File Type		Download
Filename Test Protocol.docx	Size 13.00kB	Uploaded By Jessica B Baker	File Type Protocol with Amendr	ients	Download
Filename Test SAP.docx	Size 13.00kB	Uploaded By Jessica B Baker	File Type Statistical Analysis Pla	in	Download
Filename TestFile.docx	Size 12.00kB	Uploaded By Jessica B Baker	File Type Data Dictionary		Download
How To Guide Privacy Cookie Policy EEA Disclosure Policy	Contact Us				& Copyright 2017 - 2018 Vivli

- Figure 29 Download Screen
- 4. Depending on your browser, a pop-up will appear:

Homozygous Familia Study Details Admin	I Hypercholete	pownload Data Package	Opening TestFile.docx		ansier i rotein (m	in y minibitor Bino-2010	
DOWNLOADABLE DATA PA	ACKAGE - PRESS	DOWNLOAD BUTTON FOR EACH FILE	You have chosen to open: TestFile.docx which is: Microsoft Word from: https://vivilistagewa What should Firefox do with th	Document (11.5 KB) ppi.azurewebsites.net his file?			
Filename test IPD.xlsx			Open with Microsoft V Save File	Word (default)	F	ile Type O	Download
Filename Test Protocol.docx			Do this automatically fo	or files like this from now on.	F	ile Type rotocol with Amendments	Download
Filename Test SAP.docx				OK Cancel	F	ile Type itatistical Analysis Plan	Download
Filename TestFile.docx			Size 12.00kB	Uploaded By Jessica B Baker	F	ile Type Pata Dictionary	Download

Figure 30 - Downloadable data file selection pop-up

5.0 Help and Support

5.1 Open Chat

- You can use the open chat within the data request to communicate with the Vivli team.
- Please note that messages in open chat are visible to all persons attached to a data request.
- When any other party enters a message in chat, you will receive an email notification.

5.2 Support email

If you need help with your request, please email Vivli at <u>support@vivli.org</u> and we will assist you as soon as possible. Please provide as much information as you can about your question or help needed, including the research proposal number.

If you ever have thoughts on how to improve the system or processes, please email <u>support@vivli.org</u> or reach out to Vivli via chat. When you have completed your project, Vivli will ask you to complete a short survey to help us continue to improve.